Last updated: February 19, 2026
What is ANDROGEL and its primary indications?
ANDROGEL is a topical testosterone gel indicated for testosterone replacement therapy (TRT) in adult males with hypogonadism. Manufactured by Abbott Laboratories, it is branded as a once-daily gel applied to the shoulders or upper arms. The drug gained FDA approval in 2000.
Market overview
The global testosterone replacement therapy market has been expanding. Primary drivers include increasing diagnosis of hypogonadism, growing awareness of TRT benefits, and aging populations.
- Market size (2022): Estimated at $1.6 billion.
- Growth rate (CAGR 2022–2027): 8.2%.
The North American region accounts for roughly 70% of the market, driven by high disease awareness and reimbursement coverage.
Key competitors in the testosterone gel segment
Several brands compete with ANDROGEL, including:
- Testim (Endo Pharmaceuticals)
- Axiron (Eli Lilly)
- Fortesta (Endo Pharmaceuticals)
- Natesto (containing nasal gels)
The competitive landscape is characterized by product differentiation based on delivery method, dosing convenience, and cost.
Pricing structure and reimbursement landscape
In the U.S., prescription prices for ANDROGEL vary. As of 2023:
- Average wholesale price (AWP): ~$300 per 30-gram tube.
- Average retail price: $350–$400 (after insurance adjustments).
Insurance coverage is common, but copayments range from $10 to $50 per prescription. High out-of-pocket expenses can affect patient adherence.
Reimbursement policies are dictated by Medicare and private insurance, with coverage rates exceeding 80% for prescribed testosterone therapies, incentivizing continued use.
Market penetration and prescription volume
Prescription data indicate:
- 2022 prescriptions: Approximately 1.2 million.
- Projected 2027 prescriptions: 1.8 million.
Annual growth is driven by increased screening and diagnosis of hypogonadism, which has risen correlatively with obesity and aging populations.
Price projection method and assumptions
Projections assume:
- Moderate competition continues.
- Average prices decrease marginally due to generic entries after patent expiry in 2026.
- Prescription volumes grow at a CAGR of 8.2% till 2027.
- Reimbursement rates remain stable.
Using these assumptions:
| Year |
Prescriptions (millions) |
Average Price (USD) |
Revenue (USD billions) |
| 2023 |
1.2 |
$375 |
0.45 |
| 2024 |
1.3 |
$370 |
0.48 |
| 2025 |
1.4 |
$360 |
0.50 |
| 2026 |
1.6 |
$350 |
0.56 |
| 2027 |
1.8 |
$340 |
0.61 |
Revenue projections show a compound annual growth rate (CAGR) of approximately 10% from 2023 to 2027, influenced by volume increases and slight price decreases.
Impact of patent expiry and generics
Patent expiration expected in 2026 may lead to generic versions reducing prices by 30–50%. This could impact revenue in 2027 and beyond, potentially lowering average prices to approximately $180–$200 per 30g tube.
Regulatory and policy considerations
Changes in FDA guidelines or increased safety concerns over TRT, such as cardiovascular risks, may influence prescription practices. Reimbursement policies could tighten, affecting patient access and market growth.
Risks and opportunities
Risks:
- Patent expiry and generic competition.
- Regulatory restrictions based on safety data.
- Market saturation in mature markets.
Opportunities:
- Expansion into emerging markets.
- Development of new formulations (e.g., patches, injections).
- Differentiation through convenience and safety features.
Key takeaways
- The global TRT market is robust, with growth driven by demographic trends and increased diagnosis.
- ANDROGEL's current pricing is around $300 per 30g tube, with prescriptions forecast to grow to 1.8 million by 2027.
- Revenue projections suggest growth until patent expiry, after which prices likely will decline due to generics.
- Competitive pressure and regulatory developments will shape the market landscape over the next five years.
FAQs
1. When does ANDROGEL’s patent expire?
Patent protection is expected to expire in 2026, opening the market to generics.
2. How does ANDROGEL compare price-wise to competitors?
Androgels like Testim and Fortesta have similar retail prices, typically ranging from $300 to $400 per 30g tube.
3. What factors could impact future pricing?
Generic entry, changes in insurance reimbursement, safety perception shifts, and regulatory restrictions.
4. How large is the potential market for ANDROGEL post-patent expiry?
Market volume may grow slightly due to increased diagnosis but could see price erosion reducing overall revenue.
5. Are there innovations expected in TRT delivery?
Development efforts focus on patches, long-acting injections, and nasal gels, which may influence future market dynamics.
References
[1] MarketResearch.com. (2023). Testosterone Replacement Therapy Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2023). Prescription Data for Testosterone Therapies.
[3] FDA. (2020). Reports on Testosterone Therapy Safety and Regulatory Guidelines.
[4] ExpertMarketResearch. (2022). Global Testosterone Replacement Therapy Market Forecast.
